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ABSTRACT 
The relationship between the testes and the expression 
of m~e-typical behavior has been noted throughout history. 
\ 
'--. Studies'involving castration and testosterone replacement 
' 
therapy have shown that the expression of aggression may be 
facilitated by endogenous titers of testosterone. Further 
research on the reduction of aggressive behavior involved 
the use of antiandrogens to block the androgenic effects of 
testosterone. However, researchers had neglected to 
consider important intracellular mechanisms, specifically 
the metabolism of testosterone, and the underlying 
differences in hormone sensitivity. 
In recently examining the effects of various steroid 
antagonists in male mice, we found that the widely used. 
antiandrogen, medroxyprogesterone acetate (16-alpha-methyl 
17-alpha-hydroxy progesterone acetate, MPA), administered 
in vivo, did not decrease aggression (Simon and Perry, 
1988) and did not compete with androgens for hypothalamic 
androgen receptors (unpublished data) in CF-1 male mice. 
Howev·er, Perez-Palacios, Chavez, Vilchis, Escobar, 
Larrea, and Perez (1983) found that MPA reduced androgen 
binding in vitro in thellat hypothalamus and anterior 
pituitary. To further assess the potential effectiveness 
1 
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or ineffectiveness of MPA ae an inhibitor of androgen-
androgen receptor interactions, we, therefore, studied the 
competitive effects of the drug, in vitro and in vivo, 
on androgen receptors from combined hypothalamus, preoptic 
area, and septum of CF-1 male mice. 
In Experiment I (In Vitro), neural androgen receptor 
levels were measured in the presence of a lx, lOx, lOOx, 
and lOOOx excess of one of the following radioinert 
competitors (MPA, dihydrotestosterone (DHT), or 
testosterone (T)) to determine the extent to which the 
three hormones compete with [ 3H]-DHT. In Experiment II 
(In Vivo), the mice were randomly divided among the 
following groups: (i) Control--castrated forty-eight hours 
prior to assay; (ii) Intact males+ MPA; (iii) Castrated 
males with cholesterol implant+ Oil; (iv) Castrated males 
with cholesterol implant+ MPA; (v) Castrated males with 
DHT implant+ Oil; (vi) Castrated males with DHT implant+ 
MPA. The MPA injections administered (s.c.) consisted of 
500 µg MPA and continued for twenty-four days. 
Forty-eight hours after the last injection, androgen levels 
were measured. 
·-
The results of the in vitro study indicated that, at 
the lx excess, MPA reduced the bi.nding of [ 3H]-DHT by 59% 
and competed as effectively as DHT and T for androgen 
receptors at the lOOx and lOOOx excesses. However, the 
I 
2 
reaulta of the in vivo study showed that MPA did not 
compete with [ 3H]-DHT for the androgen receptors. The 
clinical success of antagonist therapy with MPA may, 
therefore, be due to the drug's antigonadotropic effects 
and the resulting decrease in testosterone production 
rather than its antiandrogenic effects. 
3 
INTRODUCTION 
I 
Throughout history, scientists and laymen have noticed 
the relationship between the testes and male-typical 
behavior. The earliest records (described in Money and 
Ehrhardt, 1972 and Katchadourian and Lunde, 1980) of the 
sanctioned castration of males date back to ancient Egypt, 
China, and Eastern Europe. Enemy troops, upon capture, 
were castrated. Young males were ceremonially castrated 
and their genitals offered as a sacrifice to their gods. 
Others were castrated and served as guardians of harems. 
Until the early 1900's, an obscure Russian sect, the 
Skoptsy, were voluntarily castrated as a symbol of their 
faith and loyalty. During the eighteenth and nineteenth 
centuries, since women were not allowed to perform in the 
operas, the Castrati, castrated boys, served as the 
sopranos who would play the women's roles. In addition, in .,, 
1889, the French psychologist, Charles Brown-Sequard, 
consumed a testicular extract claiming that the concoction 
increased his potency, energy, and verility (Money and 
Ehrhardt, 1972: Katchadourian and Lunde, 1980). 
The first scientific observation of a relationship 
between the endocrine function of the testes and male-
typical characteristics is credited to A. A. Berthold 
4 
• (Berthold, 1849) [in Gandelman, 1984]. In the study, 
Berthold castrated six young roosters and transplanted a 
testis into the body cavity of each of the castrated 
cockere-ls. A castrated control group did not receive the 
transplant. Those receiving the testis acted and appeared 
as intact males. '~ He concluded that, since the nerve supply 
to the transplanted testis had not been reestablished, the 
function of the testes is mediated via the bloodstream (as 
described in Gandelman, 1984). In other words, testosterone 
is secreted directly into the bloodstream from the testes 
(Hadley, 1984). 
Numerous studies have, therefore, focused on the 
possible relationship between testosterone, the principle 
male hormone secreted from the testes into the bloodstream, 
and the display of male-typical behavior and aggression. 
To demonstrate the effect of a hormone on behavior, the 
secreting gland must first be removed, changes in the 
subsequent behavior noted, followed by reinduction of the 
behavior through the administration of the hormone (Sheard, 
' 1979). Mice, rats, and other mammals typically show a 
marked decrease in rank-related aggressive behavior in 
adulthood following castration performed during the first 
few weeks postpartum (Brain, 1977: Edwards and Rowe, 1975). 
According to Beeman (1947), prepubertal castration in mice 
prevents the onset of aggressive behavior while the 
5 
administration of teatoaterone (50-100 µg/kg/day) reatorea 
the levels of aggression to normal. 
Because it is now clear that the expression of 
aggression may be facilitated by endogenous titers of 
testosterone, numerous researchers have studied the 
effects of antiandrogens on aggressive behavior in rodents. 
Certain androgen antagonists--cyproterone acetate and 
medroxyprogesterone acetate--may tend to alleviate or 
decrease the display of male-typical aggressive behavior in 
rats and mice (Kurischko and Oettel, 1977: Brain, Benton, 
Goldsmith, and Bowden, 1976; Edwards, 1970; Birke and 
Sadler, 1983: Birke and Sadler, 1984). For example, 
Kurischko and Oettel (1977) found that cyproterone acetate, 
and antiandrogen, significantly decreased isolation-induced 
aggression in mature, intact SPF male mice. Testosterone 
propionate restored the levels to normal. However, 
cyproterone acetate, administered to castrated, T-
implanted aggressive mice (TO strain), decreased sex 
accessory weights of androgen-dependent target tissues 
(e.g. preputial minus sebum) but did not decrease 
aggression (Brain, et al., 1976). In addition, Edwards 
(1970) discovered that, although cyproteroneJacetate 
decreased the seminal vesicle weights in testosterone 
propionate-treated mice, the drug had no effect on 
~ aggressive behavior. .•· ;'1 
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Birke and Sadler (1983 and 1984) observed that 
medroxyprogesterone acetate (MPA), administered neonatally 
to the young via the mother's milk, decreased rough and 
tumble play levels in both male and female prepubertal 
rats. Those animals that had received the MPA were also 
less likely to initiate play and more likely to terminate 
play once it had begun. Perez-Palacios, et al. (1983) 
focused on the mechanism of action of the antiandrogen at 
the molecular level and discovered that MPA binds to 
cytosol androgen receptors in vitro in the rat 
hypothalamus and anterior pituitary indicating that MPA 
acts as an antiandrogen in neural target tissues. 
Noticing the link between the antiandrogenic effects. 
of antiandrogens and the subsequent reduction in aggressive 
behavior, scientists began to explore the possibilities of 
using antiandrogens to treat criminally violent sex 
offenders (Bradford, 1983: Pinta, 1978: Berlin and 
Meinecke, 1981; Money, Wiedeking, Walker, Migeon, Meyer, 
and Borgaonkar, 1975; Gagne, 1981; Blumer and Migeon, 
1975). Since MPA is a synthetic progestin which possesses 
antiandrogenic and antigonadotropic properties, and since 
it has been used extensively throughout the United States 
for the treatment of various medical disorders (Bradford, 
1983: van Veelen, Willemse, Sleijfer, Sluiter, and 
Doorenbos, 1985), scientists began using the drug for the 
7 
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treatment of certain groups of paraphiliaca and violent 
prisoners. Studies on the effects of MPA on sexual 
offenders indicate that, in most subjects, the drug 
decreases sexual arousal, inhibits libido and potency, 
decreases sexual fantasies and the intensity of the sexual 
drives, and reduces erotic imagery and behavior (Bradford, 
1983: Pinta, 1987: Berlin and Meinecke, 1981: Money, et 
al., 1975: Gagne, 1981: Blumer and Migeon, 1975). 
In a study of sexually deviant offenders, Gagne (1981) 
found that the drug decreased masturbatory behavior and 
frequency of erection and ejaculation while also 
significantly decreasing the desire for deviant sexual 
behavior in forty out of forty-eight subjects. However, 
for those subjects with antisocial personalities, MPA had 
no effect on deviant behavior. In addition, Blumer and 
Migeon (1975) found that 300 mg MPA, administered every 
seven to ten da:{s, decreased sexual arousal and response in 
those subjects who tend to be frequently sexually aroused 
and to a lesser degree in patients with sexual identity 
conflicts. 
According to Bradford (1983), MPA may not reduce 
aggression, per se, but rather aggression related to sex 
drive. In addition, in those cases where a significant 
reduction in aggressive or sexually deviant behavior was 
observed, plasma testosterone levels typically fell to 
8 
within the hypogonadal range (<300 ng/100 ml) aa a result 
of the chronic administration of MPA (Rubin, 1982: Berlin 
and Meinecke, 1981: Blumer and Migeon, 19751 Gagne, 1981: 
Langevin, Paitich, Bucker, Newman, Ramsay, Pope, Geller, 
and Anderson, 1979). In some instances, T levels decreased 
to levels normally associated with females (30-100 ng/100 
ml) (Cordoba and Chapel, 1983: Money, et al., 1975). In 
other words, the effects of MPA on aggressive behavior may 
be limited to that behavior which is sex drive related and 
when T levels fall to within the hypogonadal range. 
While the previously mentioned studies indicate that 
the expression of aggressive behavior may be facilitated by 
T, researchers have neglected to consider important 
intracellular mechanisms, specifically the metabolism of T. 
As testosterone enters a target cell, it can be aromatized 
into estradiol (E2 ), undergo 5-alpha-reduction to 
dihydrotestosterone (DHT), or remain as testosterone itself 
(Whalen, 1984; Munck, 1976). The metabolism of Tinto E 2 
and DHT raises the possibility of multiple mechanisms 
influencing aggressive behavior. For example, Edwards and 
Burge (1971) found that the administration of estradiol 
benzoate (EB) for five weeks to isolated, gonadectomized 
Swiss-Webster albino male mice increased aggressive 
behavior and masculine copulatory behavior. The authors 
concluded that estrogenic stimulation can be as effective 
9 
aa androgenic stimulation with respect to the arousal of 
aggression in male mice. In addition, according to Simon 
and Gandelman (1978), EB is as effective as testosterone 
propionate (TP) in promoting aggressive behavior. EB, when 
administered daily to castrated adult Rockland-Swiss male 
mice, increased attack behavior comparable to that of 
intact males or castrated males receiving injections of 
TP. 
Finney and Erpino (1976) proposed a synergistic effect \ 
between EB and dihydrotestosterone (DHT) within the central 
nervous system in the expression of aggressive behavior. 
Those mice receiving simultaneous injections of EB and DHT 
displayed aggression at levels similar to those of intact 
sham-castrates or testosterone-treated males. Multiple 
mechanisms influencing aggressive behavior are also 
available in female mice in that DHT, like TP, has the 
ability both to sensitize the perinatal central nervous 
system to T and to arouse fighting behavior in the adult 
female (Schechter, Howard, and Gandelman, 1981). Simon, 
Whalen, and Tate (1985) also state that the induction of 
male-typical aggressive behavior by testosterone in adult 
female mice is most likely mediated through its androgenic 
metabolites (T itself or DHT). Therefore, the mechanisms 
mediating aggressive behaWor may not be exclusively 
androgenic. 
10 
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Moreover, it has been noted that those mechanisms 
through which T influences aggressive behavior appear to 
vary with genotype (Whalen and Simon, 1984: Simon, 19791 
Selmanoff and Ginsburg, 1981: Shrenker and Maxson, 1983: 
Amador and Bartke, 1983: Maxson, Ginsburg, and Trattner, 
1979: Selmanoff, Abreu, Goldman, and Ginsburg, 1977; 
Selmanoff, Jumonville, Maxson, and Ginsburg, 1975; 
Selmanoff, Maxson, and Ginsburg, 1976). Depending on the 
genotype or strain and the inherent sensitivity to either 
E2 , DHT, or a combination of both metabolites, 
neuroendocrine intervention with various chemical compounds 
may have different influences on the subsequent behavior 
displayed {Whalen and Simon, 1984). In mice, for example, 
strain differ~nces and the various genotype specific 
sensitivity pathways become extremely important when 
considering chemical intervention strategies to moderate 
the display of aggressive behavior. [See Table 1 (derived 
from Simon and Whalen, 1986)]. 
( 
Strain 
CF-1 
CFW 
.co-1 
Estr7en (E2l 
+) 
(+) 
(-) 
Androyen 
+) 
(-) 
(+) 
(DHT) Testosterone 
(+) 
(+) 
(+) 
\." Table 1: Strain differences in hormone sensitivity. (+) indicates positive sensitivity. (-) indicates 
little or no sensitivity. 
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Simon and Whalen (1986) studied the aggreaaion-
promoting effects of androgens and estrogens on the 
aggressive behavior of CF-1, CFW, and CD-1 male mice. 
Genetic differences in hormone sensitivity were found among 
the different strains of mice. Castrated CF-1 and CFW 
males were shown to be sensitive to the aggression-
promoting properties of 100 µg testosterone per day while 
CD-1 males required 500 µg per day to achieve aggression 
levels comparable to those of CF-1 and CFW males. However, 
dihydrotestosterone (DHT) was effective in promoting 
aggression in the CD-1 males, moderately effective in the 
CF-1 males, and less effective in the CFW males. In 
addition, castrated CF-1 and CFW males were found to be 
responsive or sensitive to the aggression-promoting 
properties of estrogens (diethylstilbestrol and estradiol) 
while CD-1 males were relatively insensitive to the 
estrogenic treatments. According to the authors, CF-1 
males seem to be both androgenic and estrogenic sensitive 
while CFW males tend to be estrogen responsive and CD-1 
males tend to be primarily androgen responsive (Simon and 
Whalen, 1986). 
According to the diagram above (derived from the ( 
p~eviously mentioned study) and the assumptions therein, 
antiandrogen therapy would only alleviate aggression in the 
CD-1 strain. Estrogen antagonists would alleviate 
12 
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aggression in the CFW strain. Therefore, while the 
. 
functional metabolite activating aggression may be 
genetically determined, chemical intervention strategies 
used to modulate or control the display of aggressive 
behavior may have to be tailored to the underlying genotype 
and known regulatory pathways. 
In recently examining the effects of various steroid 
antagonists tailored to the known sensitivity pathways of 
these three strains of mice, Simon and Perry (1988) found 
that the widely used antiandrogen, MPA, did not decrease 
aggression in CF-1 male mice which are both androgen and 
estrogen responsive. While this lack of effect on 
aggressive behavior could be predicted based on Table 1, 
MPA was ineffective even when administered in conjunction 
with the antiestrogen, tamoxifen. The drug treatment did, 
however, significantly decrease testes and seminal vesicle 
weights (Simon and Perry, 1988). The decreased weights 
indicate that MPA blocked the growth-promoting effects of 
androgens in peripheral, androgen-dependent target tissues. 
In Simon and Perry (1988), CF-1 male mice were 
randomly divided among ·four different groups (Oil, 100, 
300, or 500 µg MPA). MPA was suspended in a .OS cc peanut 
oi 1 vehicle. Injections (·s. c.) were administered daily for 
twenty-four days. Beginning on the third day of treatment, 
the mice were tested for aggression against an intruder 
13 
(olfactory-bulbectomized CF-1 male) for ten minutes on 
alternate days for a total of ten tests. Teats consisted 
of introducing an olfactory-bulbectomized stimulus male 
into the home cage of the experimental animal for ten 
minutes. Bulbectomized males were used because they 
reliably elicit aggression comparable to that of intact 
males, although they do not initiate fighting behavior nor 
do they retaliate by counter-attacking (Denenberg, Gaulin-
--Kremer, Gandelman, and Zarrow, 1973). The fighting 
behavior displayed could, therefore, be reliably ascribed 
to the test animal. The number of attacks (biting) on the 
intruder was recorded and tallied for each animal during 
the ten minute period. After the final aggression test, 
autopsies were performed on a random sample of mice from 
each group to determine if changes in the weights of the 
testes and seminal vesicles were present as a result of the 
drug treatments. 
The results indicated that while the amount of 
.... 
fighting behavior differed across the days of testing, 
there was no significant effect of MPA dosage nor was there 
a dose x day interaction. However, treatment with MPA 
caused a significant decrease in testes weights. A trend 
analysis reveled that the weights decreased·linearly as a 
function of dosage. The analysis of seminal vesicle 
v 
weights produced similar results. While the morphological 
• 
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effects of MPA were in accord with the literature (Barbieri 
and Ryan, 1980: Neuman, von Berawordt-Wallrabe, Elger, 
Steinbeck, Hahn, and Kramer, 1970), no change in aggressive 
behavior was noted. This lack of effect on behavior is not 
surprising in light of the numerous studies that have 
demonstrated that estrogens, as 1 a product of aromatization, 
can promote aggression in many strains of mice, including 
Swiss-Webster, Rockland-Swiss, and CF-1 mice (Clarke and 
Nowell, 1979; Edwards and Burge, 1971; Simon and Gandelman, 
, 
\ 
1978; Simon and Whalen, 1986). 
An additional explanation for MPA's lack of effect on 
aggressive behavior may involve the drug's inability to 
interfere with neural androgen receptors. Preliminary 
biochemical analyses on the effects of MPA in CF-1 male 
mice revealed that the drug does not compete in vivo for 
androgen receptors in the hypothalamus, preoptic area, and 
septum (unpublished data). However, Perez-Palacios, et 
al. (1983) found that unlabeled MPA reduced the binding of 
[ 3H]-R1881, [ 3H]-DHT, and [ 3H]-T in vitro in the 
rat hypothalamus and anterior pituitary. In other words, 
MPA competed effectively with androgens for binding sites 
on the androgen receptor. The conflicting results may show 
either a species difference between rats and mice with 
respect to MPA binding or a difference between the effects 
of MPA in vitro and in vivo. The latter explanation 
15 
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aay be more plausible in that the difference between the 
in vitro and in vivo binding may be the reault of the 
metabolism of the drug in situ. 
In light of the above contradictory findings, the 
effects of MPA on neural androgen binding in CF-1 male mice 
were examined in vitro and in vivo to further assess 
the potential effectiveness or ineffectiveness of this 
compound as an inhibitor of androgen-androgen receptor 
interactions. 
METHOD 
Animals: CF-1 male mice, purchased from the Charles 
River Breeding Laboratories (Wilmington, MA), were used. 
~ 
The animals were housed in groups of four to six in 28 x 18 
x 13 cm cages with cedar shavings as bedding. Food and 
water were available ad libitum. Animals were maintained 
according to Federal guidelines on a 12:12-hr light/dark 
cycle with lights on at 0700 hr,. 
Hormones and Chemicals: Radiolabeled 5-alpha-dihydro-
[1,2,4,5,6,7 3H(N)] testosterone (S.A.=135.0 Ci/mmol) was 
obtained from New England' Nuclear {Boston, MA). 
'-....--1 
Medroxyprogesterone acetate (16-alpha-methyl 17-alpha-
16 
hydroxy progesterone ace~ate) and analytical grade reagents 
used in buffer preparations were purchased from Sigma 
Chemical Co. (St. Louis, MO). 
Receptor binding studies: Neural androgen receptor 
levels were measured using a modification of the 
hydroxylapatite method of Chamness, King, and Sheridan 
(1979) as described in Simon, Whalen, and Tate (1985). The 
mice were lightly anesthetized with ether and sacrificed by 
cervical dislocation. The brains were removed rapidly and 
blocked on ice. Combined hypothalamus, preoptic area, and 
septum were used in the assay. The section was bordered 
posteriorly by the mammillary bodies, laterally by the 
hypothalamic sulci, and anteriorly by a cut approximately 
1.5 mm anterior to the optic chiasm. The depth of the 
section was 2 mm. All remaining steps were performed at 
0-4°C. The hypothalami were homogenized (3-4 sections per 
1.1 ml) in ice cold TEGDM buffer (10 mM Tris, 1.5 mM Na 2 
EDTA, lmM dithiothreitol, 10 mM sodium molybdate, 20% 
glycerol (v/v), pH=7.4 at 0°C.) by twenty strokes • 1n a 
Teflon-glass homogenizer. The homogenate was centrifuged 
at 800g for ten minutes in a fixed-angle rotor. The 
supernatant was then centrifuged at 100,000g for one hour 
in a Beckman SWSO .1 ,rotor. The cytosol, which contains 
cellular steroid receptors released by homogenization 
(Greene, Sobel, _King, and Jensen, 1984), was used in the 
17 
aaaay. Incubations were conducted in 12 x 75 •• glaaa 
tubes that were pretreated with 0.11 BSA at room 
temperature and rinsed with cold TE (10 mM Tris, 1.5 mM 
EDTA, pH•7.4 at O•c.) prior .to use. The incubates 
consisted of 200 µl cytosol, 10 µl TEGDM with or without 
radioinert competitor, and labeled ligand ([ 3H]-DHT) 
introduced in 40 µl TEGDM. Incubations were conducted for 
14-16 hours and were terminated by introducing 250 µl of a 
hydroxylapatite (HAP: Boehringer-Mannheim Biochemicals) 
suspension (50:50 HAP:TE, v/v) into each tube. The tubes 
• 
were vortexed immediately and this step was repeated for 
ten seconds every ten minutes for thirty minutes. 
The incubates were then centrifuged in a swinging-·# 
bucket rotor for two minutes at 800g. The supernatant was 
removed by aspiration so as not to disturb the pellet. The 
HAP pellet, which contains macromolecular bound hormone, 
was washed four times with 2 ml TE containing 1% Tween-80 
(polyoxyethylenesorbitan monooleate: Sigma Chemical Co.) 
using a pumping action on the vortexer. Each wash was 
followed by a two minute centrifugation at 800g. After the 
final wash, the walls of the incubation tubes were wiped 
with ethanol and dried with cotton swabs. The washed 
pellet was extracted for six minutes with 1 ml absolute 
"' ethanol and centrifuged for two minutes. A 900 µl aliquot \_ 
was \taken and placed into a 20 ml scintillation vial. One 
18 
mililiter of absolute ethanol waa again added to the 
incubate and the procedure was repeated. The recovery of 
radioactivity was 901. Ten mililitera of toluene-based 
scintillation fluor (1 liter toluene, 4.98 g 2,5 
diphenyloxazone (PPO), 0.05 g p-bis-(2-(5-phenyloxazoyl)] 
benzene (POPOP)) were added to each sample. A Beckman 
LS-8100 liquid scintillation counter was used for counting 
with efficiency determined by the external standard 
channels ratio method. Specifically bound hormone was 
determined by subtracting nonspecific (tubes with 
competitor) from total binding (tubes without competitor). 
Protein determinations were performed using the method of 
Lowry, Rosebrough, Farr, and Randall (1951) and data were 
adjusted to dpm/mg protein. 
EXPERIMENT I -- In Vitro Competitive Binding Study: 
CF-1 male mice (80-90 days of age) were individually housed 
in 28 x 18 x 13 cm cages. In order to replicate the time 
sequence of the treatment regimen used by Simon and Perry 
(1988), the subjects were castrated under pentobarbitol 
anesthesia twenty-two days after individual housing. 
Forty-eight hours later, neural androgen receptor levels 
were measured using the method described above in the 
presence of a lx, lOx, lOOx, or lOOOx excess of one of the 
following radioinert competitors (MPA, DHT, or 
testosterone) to determine the extent to which the three 
19 
hormones compete with [ 3H]-DHT. The above doeea were 
chosen since they are logarithmic concentrations routinely 
used in in vitro preparations. 
EXPERIMENT II -- In Vivo Study: CF-1 male mice 
(80-90 days of age) were individually housed in 28 x 18 x 
13 cm cages and randomly divided among the following 
groups: (i) Control--castrated forty-eight hours prior to 
assay. This group provided baseline androgen receptor 
levels for comparison purposes. (ii) Intact males+ MPA. 
This group served as a model for the clinical adminis-
tration of the drug in patient populations. (iii) 
Castrated males with cholesterol implant+ Oil. (iv) 
Castrated males with cholesterol implant+ MPA. Groups 
(iii) and (iv) aided in determining if MPA possessed 
antiandrogenic properties when administered alone in the 
absence of androgens. (v) Castrated males with DHT implant 
+ Oil. (vi) Castrated males with DHT implant+ MPA. These 
groups allowed greater control of MPA's androgenic 
specificity. There were ten mice per group. Silastic 
implants and castrations (except for Groups (i) and (ii)) 
were performed simultaneously on the day of individual 
housing. Capsule dimensions were 10 mm long x 3 mm in 
diameter, with an inside diameter of 1 mm. The MPA 
injections administered consisted of 500 µg MPA suspended 
• 
in a .05 cc peanut oil vehicle. The mice received their 
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• 
first injections (a.c.) between 1100 and 1200 hrs one day 
after individual housing and injections continued daily for 
twenty-four days. Groups (i) and (ii) were castrated 
forty-eight hours prior to the assay. Silastic implants in 
the remaining groups were removed forty-eight hours prior 
to assay. 
J ' 
_, 
RESULTS 
The results of the in vitro study are shown in 
Figure 1 which represents the relative binding affinity of 
DHT, T, and MPA for [ 3H]-DHT labeled neural androgen 
receptors. The results indicate that, at the lx excess, 
MPA reduced the binding of [ 3H]-DHT by 59% and competed 
as effectively as DHT and T for the available androgen 
receptors at the lOOx and lOOOx excesses suggesting that 
MPA is an effective competitor for neural androgen 
• 
receptors in vitro. 
However, the results of the in vivo study showed 
that MPA did not compete with [ 3H]-DHT for hypothalamic 
'i 
androgen receptors in CF-1 male mice (See Figure 2). More 
specifically, the DHT binding of the 48 hour Control group 
and the intact males wi·th MPA implants did not differ 
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Figure 1 (In Vitro): The relative binding affinity of DHT, T, 
and MPA for [ 3H]-DHT labeled androgen receptors prepared 
from combined hypothalamus, preoptic area, and septum. 
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Figure 2 (In Vivo): The percentage of neural androgen 
binding of each group compared to its respective control. (i) Intact control group, (ii) Intact + MPA, (iii) Castrated 
with cholesterol implant + oil, (iv) Castrated with cholesterol 
implant + MPA, (v) Castrated with DHT implant + oil, 
(vi) Castrated with DHT implant + MPA. 
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aignificantly from one another. In addition, the caatrated 
male• with cholesterol implants plus oil injections did not 
differ from those receiving injections of MPA with respect 
to DHT binding. Thia indicates that MPA, administered in 
the absence of androgens, poaaeaaed neither antiandrogenic 
nor synandrogenic properties. Furthermore, the castrated 
males with DHT implants plus MPA injections also did not 
differ from their respective control group indicating that 
MPA did not decrease the binding of DHT and, therefore, is 
not an effective competitor for hypothalamic DHT receptors 
in vivo. Figure 2 represents the percentage of androgen 
binding of each group compared to its respective control 
with standard error bars shown. 
DISCUSSION 
Antiandrogens are compounds that block the effects of 
androgens at the level of the target organ (Hadley, 1984: 
Neumann and Topert, 1986). Because medroxyprogesterone 
acetate has been shown to effectively complete in vitro 
with androgens (methyltrienolone, dihydrotestosterone, 
testosterone) for binding sites on the androgen receptor in 
the rat hypothalamus ·and, anterior pituitary ( Perez-
24 
Palacios et al, 1983), the rat ovary (Pridjian, Schmit, and 
Schreiber, 1987) and the mouse kidney (Brown, Bullock, and 
Bardin, 1979), researchers began to use the drug to treat 
sexually violent criminal offenders. However, numerous 
studies have demonstrated that estrogens, as a product of 
aromatization, can promote aggression in many strains of 
mice (Clark and Nowell, 1979: Edwards and Burge, 1971: 
Simon and Gandelman, 1978: Simon and Whalen, 1986). 
Aromatization also occurs in humans (Ryan, Naftolin, Reddy, 
Flores, and Petro, 1972) and sexual behavior has been 
maintained in a castrated male by combined estrogen-
progestin treatment (Davidson, Camargo, Smith, and Kwan, 
1983) indicating that multiple sensitivity pathways (See 
Table 1) may also be available in humans. In addition, as 
the present study indicates, MPA does not compete in vivo 
with [ 3H]-DHT in the hypothalamus, preoptic area, and 
septum, those areas of the brain responsible for mediating 
aggressive behavior. 
How, then, does MPA produce its desired clinical 
effects? MPA has been shown to interfere with 5-alpha-
reductase, the enzyme responsible for the reduction of 
testosterone to its metabolite, 5-alpha-dihydrotestosterone 
(Birke, Holzhausen, Murphy, and Sadler, 1984: Massa and 
Martini, 1972). Additional studies have indicated that MPA 
also increases the metabolic clearance rate of T by 
25 
inducing 5-alpha-reductaae in the liver (Novak, Hendrix, 
Seckman, Kaiser, and Stoll, 1980: Gordon, Southren, 
Tochimoto, Olivo, Altman, Rand, and Lemberger, 1970: 
Barbieri and Ryan, 1980) which in turn increases the rate 
of degradation of the hormone. Thia increase in 
degradation leads to a reduction in the plasma 
concentration of T and thereby decreases the uptake of the 
hormone in the target organ (Albin, Vittek, Gorden, Altman, 
Olivo, and Southren, 1973). A review of the literature on 
a range of conditions shows that a positive response to 
MPA, i.e., a decrease in violence, violent fantasies, or 
deviant behavior, is seen when MPA suppresses testosterone 
levels to less than 300 ng/lOOml, a hypogonadal state 
(Cordoba and Chapel, 1983: Gagne, 1981: Meyer, et al., 
1985: Money, et al., 1975: Novak, et al., 1980). These 
observations, when combined with the likelihood that 
\ 
estrogens contribute to the maintenahce of masculine 
behavior, suggest that the primary mechanism mediating the 
ability of MPA to modulate certain behaviors may not 
. 
necessarily be its antiandrogenic effect in neural 
tissues, but rather its ability to inhibit testosterone 
synthesis coupled with its antigonadotropic action (Simon 
and Perry, 1988)~ 
MPA decreases the production rate of testosterone 
through its inhibition of the 
\ 
26 
r 
pituitary 
,_J 
~ 
secretion of 
• 
I 
I 
F / 
gonadotropina (Gordon, et al., 1970, Blumer and Migeon, 
19751 Schiff, Tulchinsky, Cramer, and Ryan, 19801 Bradford, 
1983: Novak et al., 1980: Meyer et al., 1985: Cordoba and 
Chapel, 1983: Barbieri and Ryan, 1980). MPA also has been 
found to diminish the secretion of leutenizing hormone (LH, 
the gonadotropin responsible for stimulating T-synthesia by 
the Leydig cells of the testes), thereby inhibiting 
steroidogenesis, resulting in the decreased production of T 
(Meyer, et al., 1985: Cordoba and Chapel, 1983: Barbieri 
and Ryan, 1980). Schiff, et al. (1980) reported that 20 mg 
MPA per day produced a 291 reduction in the LH levels of 
thirty-two postmenopausal women. --Gordon, et al. (1970) 
found that 10 mg MPA, administered orally four times a day 
to normal adults, significantly decreased plasma LH and T 
levels. MPA also decreased LH and T concentrations and 
abolished sexual arousal in patients treated for sex 
deviations (Blumer and Migeon, 1975). Bradford (1983) also 
noted that MPA decreases the production rate of T by 
inhibiting the pituitary secretion of LH and it is this 
reduction in circulating T that most likely causes the 
decrease in the sex drive. 
Based on the previous observations and the results of 
the present study, it· seems reasonable to suggest that the 
clinical success of antagonist therapy with MPA is due to 
the drug's antigonadotropic effects and the resulting 
27 
\ 
' 
decrease in teatoaterone production. Alternative 
pharmacological treatments that are more specific than MPA 
(e.g., antigonadotropins, gonadotropin-releaaing hormone 
antagonists) may prove even more useful in the management 
of aggressive and/or deviant behaviors (Simon and Perry, 
1988). 
The gonadotropin-releasing hormone (GnRH), for 
example, stimulates the release of pituitary gonadotropins 
(LH, FSH) thereby regulating the release of testosterone 
from the testes or e~trogen from the ovaries. A 
gonadotropin-releasing hormone antagonist would, therefore, 
ultimately decrease the production of testosterone or 
estrogen. GnRH antagonists, which decrease the circulating 
levels of gonadotropins and, consequently, testosterone, 
are currently being used in the treatment of hormonally 
related conditions such as hormone-dependent cancers, 
precocious puberty, endometriosis, and for the control of 
fertility (Glode, 1986: Adams, Bremner, Nestor, Vickery, 
and Steiner, 1986). Studies indicate that GnRH antagonists 
significantly decrease LH and T levels in male frogs (Rana 
esculenta) (Di Matteo, Minucci, Fasano, Pierantoni, 
Varriale, and Chieffi, 1988), rats (Bhasin, Fielder, and 
Swerdlqff, 1987), and monkeys (Macaca fascicularis) 
\ (Adams, et al., 1986). In addition, Jockenhovel, Bhasin, 
Steiner, Rivier, Vale, and Swerdloff (1988) foun~ that at 
28 
single doaea of 0.5, 1.5, and 5.0 mg, Nal-Glu GnRH 
antagonist significantly reduced serum LH and T 
concentrations of six normal men in a dose dependent 
manner with T levels falling to 201 of baseline at the 5.0 
mg dose. 
Pavlou, Debold, Island, Wakefield, Rivier, Vale, and 
Rabin (1986) studied the effects of an LHRH antagonist 
(4F-antagonist) on the gonadotropin and T levels of normal 
men. Following the administration of the 
\ 
\_ . ~ fell to as low as 45.31 or~ baseline while 
drug, LH levels 
T levels were 
reduced to 76.01 of .baseline. In addition, a study of 
prostatic cancer patients receiving long-term treatment 
with GnRH antagonists showed that the testes had less than 
51 of the T-producing capacity than those of normal 
controls. Although gonadotropin and androgen production 
decreased in the patients, responsiveness to exogenous 
' 
gonadotropins could be maintained (Huhtaniemi, Nikula, 
Rannikko, and Clayton, 1986). 
Therefore, since 1the clinical success of antagonist 
therapy with MPA is most likely due to the drug's 
antigonadotropic effects and the resulting decrease in T 
production, GnRH antagonists, which tend to be more 
\ 
specific than MPA, may prove even more useful in the 
treatment of aggressive or· deviant behaviors. When 
considering chemical intervention strategies to modulate 
29 
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the diaplay of aggressive behavior, researchers should 
focus not on reducing neural androgen binding, per ae, but 
on lowering testosterone levels by decreasing its 
production or synthesis. 
A word of caution should also be noted regarding the 
preliminary testing of drugs which normally involve in 
vitro preparations. As the present study indicates, MPA 
is an effective competitor for neural androgen receptors 
in vitro, but not in vivo, which may be the result of 
the metabolism of the drug in situ. Therefore, while 
the preliminary testing of a proposed clinical drug 
typically involves in vitro preparations, the results of 
this study stress the importance of adequate pretesting 
regimens that should include not only in vitro 
preparations, but also in vivo administration of the 
drug across a number of animal models and strains. 
30 
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